ArticleEJNMMI research2026
Estimation of split renal function using [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhysiological prostate-specific membrane antigen (PSMA) expression in renal proximal tubules results in radiopharmaceutical uptake in PSMA-PET, suggesting the potential to assess renal function. To evaluate split renal function derived from [18F]F-flotufolastat ([18F]F-rhPSMA-7.3) PET/CT and to systematically compare its performance with [68Ga]Ga-PSMA-11 PET/CT and the reference standard [99mTc]Tc-MAG3 scintigraphy, we retrospectively analyzed 302 patients with metastatic castration-resistant prostate cancer undergoing PSMA-PET/CT using either [18F]F-flotufolastat (n = 221) or [68Ga]Ga-PSMA-11 (n = 81), along with [99mTc]Tc-MAG3 scintigraphy, prior to PSMA radioligand therapy. SRF was calculated from PSMA-PET/CT using mean standardized uptake values and CT-derived renal volumes. SRF was calculated from [99mTc]Tc-MAG3 using standard integral analysis. SRF derived from PSMA-PET/CT ([18F]F-flotufolastat and [68Ga]Ga-PSMA-11) was correlated with split renal function obtained from [99mTc]Tc-MAG3 scintigraphy on a side-specific basis using Pearson correlation and Bland–Altman analysis. Receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic performance for detecting impaired renal function (SRF ≤ 25% and ≤ 40%). A PET-based accumulation index (ACI) was explored in relation to estimated glomerular filtration rate (eGFR) in an exploratory, tracer-specific analysis.
resultsStrong correlations were found between PET-SRF and [99mTc]Tc-MAG3-SRF (r = 0.88 for [18F]F-flotufolastat, r = 0.85 for [68Ga]Ga-PSMA-11; both p < 0.0001). Bland–Altman analysis showed a smaller mean bias and narrower limits of agreement for [18F]F-flotufolastat (-0.56%; -11.88% to + 10.75%) compared with [68Ga]Ga-PSMA-11 (-1.18%; -15.3% to + 12.95%), with 92% versus 83% of values within ± 10%, respectively. ROC analysis confirmed excellent accuracy for identifying [99mTc]Tc-MAG3-SRF ≤ 25% (area under the curve [AUC] = 0.997 for [18F]F-flotufolastat; AUC = 0.942 for [68Ga]Ga-PSMA-11). No significant association was observed between ACI and eGFR for either radiopharmaceutical ([18F]F-flotufolastat: Spearman’s ρ = 0.056, p = 0.414; [68Ga]Ga-PSMA-11: Spearman’s ρ = − 0.071, p = 0.536).
conclusionPSMA-PET/CT provides reliable estimates of SRF, with [18F]F-flotufolastat showing slightly superior agreement with [99mTc]Tc-MAG3 scintigraphy. This may potentially eliminate the need for additional renal scintigraphy for SRF assessment in the future and may simplify workflows and reduce patient burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.